$CTEV

Claritev Q2 Earnings Call Highlights

Claritev (NYSE:CTEV) reported Q2 No Surprises Act-related revenue growth attributed mainly to one client, with management saying claim mix drove lower charges per claim. Bookings were $30M ACV in Q2 and $74M in H1, exceeding 2025 total and targeting over $100M for FY. FY revenue guidance raised to $1.00B-$1.02B and adjusted EBITDA to $610M-$620M.

Original reporting
Published Aug 9, 2026, 8:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 9, 2026, 8:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Claritev Q2 Earnings Call Highlights — source image
Decision brief

The 30-second read

$CTEVBullishMed
01

Why it matters

The Q2 call highlights stronger bookings and pipeline, plus raised FY revenue, EBITDA, and free-cash-flow outlook, with AI initiatives aimed at reducing IDR administrative costs.

02

Market read

Traders can reprice Claritev’s growth and margin expectations based on raised FY guidance and bookings/pipeline acceleration, while monitoring the flat sequential Q3 revenue comment.

03

What to watch

About 75% of bookings come from cross-sell/upsell, so churn or consolidation risk at existing clients could matter more than new-logo growth.

Relevance 8/10Novelty 8/10Timing: pre-market today, Q2 call guidance update

Background

Claritev provides healthcare network, payment integrity, and related solutions tied to claims repricing and No Surprises Act workflows.

Company-level read

Ticker impact

$CTEVBullishMedium confidence
Context

Claritev raised full-year revenue guidance to $1.00B-$1.02B and adjusted EBITDA to $610M-$620M after Q2 performance.

Expected impact

Likely positive near-term bias as guidance and bookings targets reset expectations, though execution risk remains given multi-quarter revenue ramp.

Evidence & confidence

The article provides specific, time-sensitive guidance ranges and bookings/pipeline metrics, which typically move valuation expectations for growth and margin trajectory.

Market effects

Reinforces demand for healthcare payment integrity and No Surprises Act workflow platforms, supporting sentiment for adjacent healthcare data/claims repricing vendors.

No clear regional-specific impact described.

Primarily US regulatory-driven demand (No Surprises Act), limited direct global read-through in the text.

Counterpoint

Guidance is raised but Q3 revenue is guided roughly flat sequentially, implying near-term growth may still be uneven.

Key entities

  • Claritev

    Healthcare technology and data insights provider focused on affordability, transparency, and payment integrity.

  • Travis Dalton

    CEO who discussed TPA contracts, Medicare Advantage network build, and AI initiatives.

  • Garis

    Speaker who discussed No Surprises Act revenue drivers, bookings mix, and ProPricer AI savings.

Related articles

$CTEVMed

Claritev Corp (CTEV): Results of Operations and Financial Condition

Claritev Corp (CTEV) filed an SEC Form 8-K — Results of Operations and Financial Condition. E Claritev Corporation Reports Second Quarter 2026 Results – Q2 2026 Revenues of $257.5 million grew 6.6% compared to Q2 2025 – Net Loss of $59.2 million – Adjusted EBITDA of $155.8 million increased 1.1% compared to Q2 2025 (Adjusted EBITDA Margin of 60.5% versus 63.8% in Q2 202

Med

DroneShield Shares Down 50% This Year, As Pressure Builds

DroneShield (ASX: DRO) shares have fallen 50% in 2026, despite a 74% revenue increase to A$125.8M. The company reported a net loss of A$32.2M, causing concern about profitability. Brokers have mixed price targets, ranging from A$1.50 to A$2.60. The stock trades at A$1.66, below the A$1.70 support level.

$KBHMedAI 8/10

KB Home’s (NYSE:KBH) Q3 CY2026 Earnings Results: Revenue In Line With Expectations But Full-Year Sales Guidance Misses Expectations

KB Home (NYSE: KBH) reported Q3 CY2026 revenue of $1.30B, meeting expectations but down 20% YoY. Full-year guidance of $5B missed estimates by 2%. EPS of $1.05 beat estimates by 16.7%. The company highlighted progress in its Built to Order business and community count growth. Analysts expect 6.5% revenue growth and 19.7% EPS growth over the next 12 months.

$KBHHigh

Why is KB Home stock sliding today?

KB Home stock fell 2.7% in after-hours trading after reporting fiscal Q3 earnings. EPS beat estimates at $1.05, but revenue of $1.3B dropped 20% YoY. Full-year revenue guidance was 2% below expectations. Operating and gross profit margins declined, and net orders fell 12% YoY. The company cited weakening conditions and higher mortgage rates. Ending backlog rose, and $50M in stock was repurchased. The stock had already declined over 20% in the past year.